Wells Fargo’s Medicenna Therapeutics Corp. Common Shares MDNA Stock Holding History

Wells Fargo’s Portfolio MDNA Stock Details MDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-715	Closed	-$211	–	7816
2023 Q3	$211	Hold	715	–	–	﹤0.01%	6569
2023 Q2	$346	Hold	715	–	–	﹤0.01%	6560
2023 Q1	$465	Buy	+715	New	+$445	﹤0.01%	6569

Other funds holding MDNA

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

NDSI

Newman Dignan & Sheerar Inc Providence, Rhode Island $523M AUM 26.16% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Wells Fargo's MDNA Position: Q4 2023 in Review

Wells Fargo sold out of Medicenna Therapeutics Corp. Common Shares (MDNA) in Q4 2023, closing a stake of 715 shares — an estimated $211 sold.

Wells Fargo first reported a position in MDNA in Q1 2023 and held it in 3 quarters. The position peaked at $465 in Q1 2023. 3 funds tracked by Wall St. Rank hold MDNA as of Q4 2023.

Wells Fargo reported no remaining Medicenna Therapeutics Corp. Common Shares position as of Q4 2023 after selling out during the quarter.
Wells Fargo sold 715 Medicenna Therapeutics Corp. Common Shares shares in Q4 2023, an estimated $211.
Wells Fargo first reported a position in Medicenna Therapeutics Corp. Common Shares in Q1 2023 and held it in 3 quarters.
Wells Fargo's Medicenna Therapeutics Corp. Common Shares position peaked at $465 in Q1 2023.
3 funds tracked by Wall St. Rank held Medicenna Therapeutics Corp. Common Shares as of Q4 2023.

Based on Wells Fargo's 13F filing for Q4 2023, filed 9 Feb 2024.